UT HB0390

Huntsman Mental Health Institute at the University of Utah is authorized to conduct a clinical study on psychedelic-assisted therapy (MDMA, psilocybin, or 5-methoxy-N,N-dimethyltryptamine) for veterans with treatment-resistant PTSD

The study must begin by January 1, 2027 if sufficient funding is secured through a combination of legislative appropriations and private donations; the Institute may continue accepting donations after that date

The study must comply with FDA investigational new drug requirements, DEA Schedule I research registration, and Institutional Review Board approval before beginning

Huntsman must report progress to the Health and Human Services Interim Committee upon request and submit a final written report on safety, feasibility, and clinical outcomes after the study concludes

Unused donated funds must be returned to donors by July 1, 2032; the bill's provisions sunset on July 1, 2032; no state money is appropriated in the bill